| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 10/25/2001 | WO2001079469A2 Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses |
| 10/25/2001 | WO2001079468A2 Drug metabolizing enzymes |
| 10/25/2001 | WO2001079455A1 Kv10.1, A NOVEL VOLTAGE-GATED POTASSIUM CHANNEL FROM HUMAN BRAIN |
| 10/25/2001 | WO2001079451A1 Methods and compositions for culturing spirochetes and treating spirochetal diseases |
| 10/25/2001 | WO2001079448A2 Trp8, a transient receptor potential channel expressed in taste receptor cells |
| 10/25/2001 | WO2001079299A1 Enhancement of antibody-mediated immune responses |
| 10/25/2001 | WO2001079291A2 Secreted proteins |
| 10/25/2001 | WO2001079288A2 Cytokine uses; compositions; methods |
| 10/25/2001 | WO2001079282A2 Molecules associated with human reproduction |
| 10/25/2001 | WO2001079269A2 Lipid binding protein 4 |
| 10/25/2001 | WO2001079170A2 Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof |
| 10/25/2001 | WO2001079164A2 N-substituted dithiocarbamates for the treatment of biological disorders |
| 10/25/2001 | WO2001079156A1 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| 10/25/2001 | WO2001078803A1 Systems, kits, and methods of administering synthetic plasma |
| 10/25/2001 | WO2001078783A2 Compositions comprising natural agents for treatment of cancer |
| 10/25/2001 | WO2001078782A1 Single-dose antihistamine/decongestant formulations for treating rhinitis |
| 10/25/2001 | WO2001078781A2 Methods for prevention and treatment of gastrointestinal disorders |
| 10/25/2001 | WO2001078760A2 Method for treating pain by peripheral administration of a neurotoxin |
| 10/25/2001 | WO2001078750A1 Lice remover composition |
| 10/25/2001 | WO2001078746A1 Respiratory compositions |
| 10/25/2001 | WO2001078743A1 Medical combinations comprising tiotropium and mometasone |
| 10/25/2001 | WO2001078737A1 Medical combinations comprising formoterol and budesonide |
| 10/25/2001 | WO2001078736A1 Medical combinations comprising tiotropium and rofleponide |
| 10/25/2001 | WO2001078730A1 Methods and compositions useful in enhancing oxygen delivery to cells |
| 10/25/2001 | WO2001078724A1 Rapid-onset formulation of a selective cyclooxigenase-2 |
| 10/25/2001 | WO2001078721A1 Aβ42 LOWERING AGENTS |
| 10/25/2001 | WO2001078711A2 Pde-v inhibitors for treatment of parkinson's disease |
| 10/25/2001 | WO2001078709A2 Treatment of neurodegenerative disease |
| 10/25/2001 | WO2001078708A1 Treating graft rejection with cxcr3 inhibitors |
| 10/25/2001 | WO2001078707A1 Treating graft rejection with ccr5 inhibitors |
| 10/25/2001 | WO2001078706A2 Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism |
| 10/25/2001 | WO2001078705A2 Compositions containing a naphthalmide and an antiproliferative agent |
| 10/25/2001 | WO2001078700A2 Compositions for use in modulating immune system function comprising at least one retrinoid and at least one cytokine |
| 10/25/2001 | WO2001078699A2 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations |
| 10/25/2001 | WO2001078698A2 Use of ngf-antagonists for the prevention or treatment of chronic visceral pain |
| 10/25/2001 | WO2001078697A2 Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists |
| 10/25/2001 | WO2001078696A2 Formulations for use in inhaler devices |
| 10/25/2001 | WO2001078678A1 Pre-formed sheet devices suitable for topical application |
| 10/25/2001 | WO2001078677A1 Use of alcohol dehydrogenase inhibitors for cosmetic treatment of keratinous materials |
| 10/25/2001 | WO2001078653A2 Graft rejection inhibition with ccr2 inhibitors |
| 10/25/2001 | WO2001078651A2 Method for treating neoplasmin with topoisomase i inhibitor |
| 10/25/2001 | WO2001078580A2 A method combining inducing hypothermia and administering a therapeutic agent |
| 10/25/2001 | WO2001078533A2 Nutritional modules |
| 10/25/2001 | WO2001044246A8 Bicyclic inhibitors of glycogen synthase kinase 3 |
| 10/25/2001 | WO2001041778B1 Melanin synthesis inhibition compound and composition containing the same |
| 10/25/2001 | WO2001040499A3 Methods for cell screening of compounds capable of modulating the activity of ubiquitin-ligase scf complexes and their uses |
| 10/25/2001 | WO2001024684A3 Methods for treatment of solid tumors and metastasis by gene therapy |
| 10/25/2001 | WO2001023570A3 Methods and compositions relating to sodium channel beta-1a subunits |
| 10/25/2001 | WO2001022950A3 Diosolane nucleoside analogs for the treatment or prevention of viral infection |
| 10/25/2001 | WO2001022092A3 Method to identify compounds which modulate fra-1 expression fils |
| 10/25/2001 | WO2001021154A3 Surface modified particulate compositions of biologically active substances |
| 10/25/2001 | WO2001012790A3 Isomerase proteins |
| 10/25/2001 | WO2001012663A3 Hematopoietic regulatory factors and methods of use thereof |
| 10/25/2001 | WO2001000245A3 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 10/25/2001 | WO2000057187A9 Diagnosis and treatment of multiple sclerosis |
| 10/25/2001 | WO2000056737A9 Calanolides for inhibiting btk |
| 10/25/2001 | WO2000047618A9 HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES |
| 10/25/2001 | WO2000047104A3 Antagonists of hmg1 for treating inflammatory conditions |
| 10/25/2001 | WO2000011169A3 Human cell signaling proteins (csig) |
| 10/25/2001 | US20010034884 Abeta-peptide screening assay |
| 10/25/2001 | US20010034440 Complexing the target cell with therapeutic agent; antiproliferative agent |
| 10/25/2001 | US20010034436 Polynucleotide and polypeptides, screening for antibiotic activity, Staphylococcus |
| 10/25/2001 | US20010034372 Treatment of fibromyalgia with ubiquinone 10 and succinic acid |
| 10/25/2001 | US20010034364 Isoprenoid pathway inhibitors for stimulating bone growth |
| 10/25/2001 | US20010034362 Pyrrolidine derivatives for vision and memory disorders |
| 10/25/2001 | US20010034361 Amide derivatives for antiangiogenic and/or antitumorigenic use |
| 10/25/2001 | US20010034359 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
| 10/25/2001 | US20010034358 Human immunodeficiency syndrone, hepatitis virus |
| 10/25/2001 | US20010034356 Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor |
| 10/25/2001 | US20010034353 Administering a mixture of antibiotic, nonsteroid antiinflammatory drug and a quinolone compound |
| 10/25/2001 | US20010034349 Methods of hydrating mucosal surfaces |
| 10/25/2001 | US20010034347 A pyrido(1,2-a)pyrazine compound |
| 10/25/2001 | US20010034345 Administering a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid |
| 10/25/2001 | US20010034344 Use of known agonists of the central cannabinoid receptor CB1 |
| 10/25/2001 | US20010034339 For eyes, ears or noses |
| 10/25/2001 | US20010034338 Administering synergistic mixture of phytosterol and policosanol |
| 10/25/2001 | US20010034337 Antiproliferative agents |
| 10/25/2001 | US20010034334 Genetic engineered polypeptide |
| 10/25/2001 | US20010034327 Suppression of inhibitors |
| 10/25/2001 | US20010034320 Administering neurokinin 1 (NK1)-receptor antagonist |
| 10/25/2001 | US20010034051 For example: (2-(3-amino-4-nitrophenyl)amino)ethyl)(6-(2,4-dichlorophenyl-5-nitropyrazin -2-yl)-amine; antidiabetic, -carcingenic and ischemic agents; nervous and cardiovascular system disorders; immunotherapy; obesity; syndromes |
| 10/25/2001 | US20010034032 Determining a subject's susceptibility to or the rapidity of progression of sepsis in a subject by detecting at least one allele of an Interleukin-1 proinflammatory haplotype in a nucleic acid sample which indicates increased susceptibility |
| 10/25/2001 | US20010033872 Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and St. John's Wort for the treatment of mental disturbances |
| 10/25/2001 | US20010033867 Systems and methods for local delivery of an agent |
| 10/25/2001 | US20010033856 High protein |
| 10/25/2001 | US20010033838 Animal derived lipid |
| 10/25/2001 | US20010032643 Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage |
| 10/25/2001 | DE10018834A1 Transdermal or transmucosal pharmaceutical dosage form for treatment of nicotine dependence or smoking withdrawal contains nicotine compound or substitute and CNS active compound |
| 10/25/2001 | DE10018401A1 Medicament for treating hypertrophy-related myocardial disease, containing bradycardic agent, preferably cilobradine, and optionally another cardiac drug |
| 10/25/2001 | CA2575059A1 Pharmaceutical compositions comprising cilobradine |
| 10/25/2001 | CA2485920A1 Method for treating pain by peripheral administration of a neurotoxin |
| 10/25/2001 | CA2485919A1 Method for treating pain by peripheral administration of a neurotoxin |
| 10/25/2001 | CA2407031A1 Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease |
| 10/25/2001 | CA2406947A1 Methods for prevention and treatment of gastrointestinal disorders |
| 10/25/2001 | CA2406481A1 Trp8, a transient receptor potential channel expressed in taste receptor cells |
| 10/25/2001 | CA2406390A1 Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase |
| 10/25/2001 | CA2406383A1 A.beta.42 lowering agents |
| 10/25/2001 | CA2406245A1 Il-174 uses, compositions and methods |
| 10/25/2001 | CA2406226A1 Rapid-onset formulation of a selective cyclooxigenase-2 |
| 10/25/2001 | CA2406195A1 Lipid binding protein 4 |